48,868
edits
Difference between revisions of "Programmed cell death 1"
Jump to navigation
Jump to search
→IHC
(→IHC) |
(→IHC) |
||
| Line 34: | Line 34: | ||
*There is no standard PD-1 antibody; each drug company has its own clone. | *There is no standard PD-1 antibody; each drug company has its own clone. | ||
*Nivolumab: PD-L1 28-8: provides prognostic inflammation, may benefit without staining.<ref>{{Cite journal | last1 = Borghaei | first1 = H. | last2 = Paz-Ares | first2 = L. | last3 = Horn | first3 = L. | last4 = Spigel | first4 = DR. | last5 = Steins | first5 = M. | last6 = Ready | first6 = NE. | last7 = Chow | first7 = LQ. | last8 = Vokes | first8 = EE. | last9 = Felip | first9 = E. | title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | journal = N Engl J Med | volume = 373 | issue = 17 | pages = 1627-39 | month = Oct | year = 2015 | doi = 10.1056/NEJMoa1507643 | PMID = 26412456 }}</ref> | *Nivolumab: PD-L1 28-8: provides prognostic inflammation, may benefit without staining.<ref>{{Cite journal | last1 = Borghaei | first1 = H. | last2 = Paz-Ares | first2 = L. | last3 = Horn | first3 = L. | last4 = Spigel | first4 = DR. | last5 = Steins | first5 = M. | last6 = Ready | first6 = NE. | last7 = Chow | first7 = LQ. | last8 = Vokes | first8 = EE. | last9 = Felip | first9 = E. | title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | journal = N Engl J Med | volume = 373 | issue = 17 | pages = 1627-39 | month = Oct | year = 2015 | doi = 10.1056/NEJMoa1507643 | PMID = 26412456 }}</ref> no for squamous, ? non-squamous | ||
*Pembrolizumab: PD-L1 22C3:<ref>{{Cite journal | last1 = Garon | first1 = EB. | last2 = Rizvi | first2 = NA. | last3 = Hui | first3 = R. | last4 = Leighl | first4 = N. | last5 = Balmanoukian | first5 = AS. | last6 = Eder | first6 = JP. | last7 = Patnaik | first7 = A. | last8 = Aggarwal | first8 = C. | last9 = Gubens | first9 = M. | title = Pembrolizumab for the treatment of non-small-cell lung cancer. | journal = N Engl J Med | volume = 372 | issue = 21 | pages = 2018-28 | month = May | year = 2015 | doi = 10.1056/NEJMoa1501824 | PMID = 25891174 }}</ref> IHC testing necessary to use in USA. | *Pembrolizumab: PD-L1 22C3:<ref>{{Cite journal | last1 = Garon | first1 = EB. | last2 = Rizvi | first2 = NA. | last3 = Hui | first3 = R. | last4 = Leighl | first4 = N. | last5 = Balmanoukian | first5 = AS. | last6 = Eder | first6 = JP. | last7 = Patnaik | first7 = A. | last8 = Aggarwal | first8 = C. | last9 = Gubens | first9 = M. | title = Pembrolizumab for the treatment of non-small-cell lung cancer. | journal = N Engl J Med | volume = 372 | issue = 21 | pages = 2018-28 | month = May | year = 2015 | doi = 10.1056/NEJMoa1501824 | PMID = 25891174 }}</ref> IHC testing necessary to use in USA. | ||
*Atezolizumab <ref name=pmid26970723>{{Cite journal | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume = 387 | issue = 10030 | pages = 1837-46 | month = Apr | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref> - testing required. | |||
*Durvalumab: testing required. | |||
==See also== | ==See also== | ||